Novopyxis is an award-winning biotechnology company dedicated to the development of therapeutics and medical devices. Novopyxis’ flagship drug was developed using in-house proprietary mathematical algorithms and has been validated across several different in vitro, ex vivo and in vivo models. It activates a key anti-inflammatory receptor called the AT2R and is both cardioprotective and neuroprotective. Our therapeutic was recently awarded an orphan designation for "Pediatric Cardiomyopathy" from the FDA.
Droplette was recently spun out from Novopyxis (www.droplette.io) and is focused on development of a patented medical device for delivery of large molecules, DNA/RNA, and proteins deep through skin, tissue, and cells. We are currently partnered with Leo Pharma for development of our device for medical dermatology applications and have won several awards:
- 2015 Graduate of MassCONNECT program via MassBio
- 2015 Amgen Golden Ticket Winner
- 2014 Mass Challenge Finalist
- Winner of 2014 CASIS-Boeing Prize for Technology in Space
- Second place winner in 2015 M2D2 New Ventures Competition
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2013
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Novopyxis founded?
Novopyxis was founded in 2013.
What industry is Novopyxis in?
Novopyxis operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Novopyxis based?
Novopyxis is headquartered in Cambridge, United States.
Find investors for your startup like Novopyxis
Gritt sends AI-personalised outreach to each investor — from your Gmail
